Core One Labs’ Akome Takes Another Step in the Development of Its Psychedelic Drug Formulations and Announces Positive Results from Neuro-Pharmacokinetic Studies


VANCOUVER, BC / ACCESSWIRE / August 19, 2022 / Core One Labs Inc. (CSE:COOL), (OTCQB:CLBF), (Frankfurt:LD6WKN:A3CSSU) (the “Company” Where “core one“) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome“) through its formalized research agreement with the Fundación Medina in Granada, Spain (“Medina Foundation“) has received very encouraging results from ongoing pharmacokinetic studies. The study results represent another important milestone in the company’s preclinical development of its psychedelic-based bioactive compounds designed to target major depressive disorder (“The Depression“), stroke, Parkinson’s disease (“DB“) and Alzheimer’s disease (“AD“), and justify advancing the formulations along the development pipeline.

Pharmacokinetics studies absorption, distribution, metabolism and excretion (“ADD ME“) of drugs in humans, and also tests for toxic effects (“TOX“) of the drug candidate on the systems or organs of the body. These studies are paramount in drug discovery and development because they reduce the risks of drug candidate compounds and ultimately improve their productivity. When compounds are developed for the treatment of neurological and mental health disorders, it is also essential to determine the tissue concentration and behavior in the brain of the candidate compounds, which is called neuro-pharmacokinetics.

Very encouraging results from ADME/TOX neuro-pharmacokinetic studies, conducted by Fundación Medina, show that Akome’s bioactive compounds tested in controlled environments work very well, increasing the level of confidence scientists need to understand the potential efficacy of Akome’s drug candidates, and advancing our drug discovery process along the development continuum toward regulatory approval.

“Core One’s scientists and research partners are seeing positive results at every stage of our preclinical drug trials, and we are excited about the progress Akome has made in advancing its psychedelic-based formulations through the development pipeline,” said Joel Shacker, CEO of Core One Labs.

“The results presented today, combined with the positive bioassay results presented by the Company in April, demonstrate the significant potential of our drug formulations. I am confident that Akome scientists, along with their research partners, will continue to deliver strong results based on their track record of success,” he added again.

About the Medina Foundation

Fundación Medina is a renowned independent and non-profit research center for innovative biopharmacology and a reference center for the discovery of drugs based on natural products. Its research activities are carried out by a large group of multidisciplinary scientists in a state-of-the-art facility in Granada, Spain. Fundación Medina has extensive experience in drug discovery and focuses its research on high-throughput screening programs in strategic therapeutic areas: infectious and parasitic diseases, oncology and neurodegeneration. Fundación Medina seeks to discover new bioactive compounds and innovative therapies for unmet medical and industrial needs.

About Core One Labs Inc.

Core One is a biotechnology research and life science technology company focused on bringing psychedelic drugs to market through novel delivery systems and psychedelic-assisted psychotherapy. Core One has developed a patent-pending thin-film oral strip (the “Technology”) that dissolves instantly when placed in the mouth and delivers organic molecules in precise amounts into the bloodstream, maintaining excellent bioavailability . The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also has interests in medical clinics that maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for the disorders of mental health.

Core One Labs Inc.

Joel Shacker
Chief executive officer


[email protected]


The Canadian Securities Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the content of this press release.

The information in this press release contains forward-looking statements based on assumptions as of the date of this press release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the Company’s control. These factors include, among others: the risks and uncertainties associated with the Company’s limited operating history and the need to comply with stringent regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied by the forward-looking information. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offense to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One has no direct or indirect involvement in the illegal sale, production or distribution of psychedelic substances in the jurisdictions in which it operates. Although Core One believes that psychedelics can be used to treat certain medical conditions, it does not advocate the legalization of psychedelics for recreational use. Core One does not deal with psychedelics except in laboratory and clinical trials conducted under approved regulatory frameworks.

THE SOURCE: Core One Labs Inc.

See the source version on Neuro-pharmacokinetic studies


Comments are closed.